Hereditary cancer, somatic genomics, and treatment-relevant findings. New BRCA / Lynch / TP53 evidence, novel targeted therapies, and clinical-trial readouts.
36 stories · Last updated
The US Food and Drug Administration has reversed its earlier opposition, allowing UniQure to file its investigational RNA-interference treatment for Huntington's disease for regulatory review.
A preprint using structural modelling across more than one million genomes classifies over 600 ARID1B missense variants as damaging to protein interactions or stability, offering a resource for interpreting the large majority of variants that currently lack clinical classification.
The US Food and Drug Administration has reversed its earlier rejection and will re-examine Regenxbio's experimental gene therapy for Hunter syndrome, a rare and life-limiting childhood disorder.
A preprint describes nanoASM, a framework using whole-genome nanopore sequencing to simultaneously profile germline variants and allele-specific methylation, identifying noncoding regulatory changes in normal and tumour prostate tissue.
Cancer Research UK reports that new data provide the strongest evidence to date that the UK HPV vaccination programme is reducing not only cervical cancer incidence but cervical cancer mortality.
A preprint from Cold Spring Harbor Laboratory applies saturation genome editing to reclassify more than 9,000 variants of uncertain significance in two hereditary cancer genes.
Researchers report that EXO1, a gene ordinarily involved in DNA repair, becomes damaging when cells produce too much of it — cutting DNA inappropriately and creating a potential vulnerability that may be exploitable in cancer research.
Researchers report that somatic mutations associated with haematological malignancies could trigger neuroinflammation implicated in Alzheimer's disease, suggesting a previously unrecognised mechanistic overlap between the two conditions.
The world's first randomised trial of a multi-cancer early detection blood test did not meet its primary endpoint, though commentators argue the results carry important signals for the field of early-detection genomics.
Phase 3 results for Revolution Medicines' daraxonrasib show a 60% reduction in risk of death compared with standard chemotherapy, marking the first practice-changing advance for KRAS-mutant pancreatic cancer.
The UK National Screening Committee has endorsed a risk-stratified approach to prostate cancer screening, focusing on men who carry a BRCA2 pathogenic variant and have a relevant family history of cancer.
Researchers have identified a compound that blocks the DNA repair mechanism cancer cells exploit to survive treatment, potentially reversing resistance to PARP inhibitor therapies.
The antibody-drug conjugate mirvetuximab soravtansine has been added to the NHS England treatment portfolio for platinum-resistant ovarian cancer — the first new approved option in this setting in more than two decades.
A preprint from Cold Spring Harbor Laboratory describes genome-wide pairwise disruption of 233 DDR genes in cancer-relevant cell lines, revealing how repair pathway components interact functionally.
A preprint reports that 4% of Rwandan breast cancer cases in a 175-woman cohort carry a single recurrent BRCA1 frameshift variant tracing to a common ancestral haplotype of around 581 kb.
Daraxonrasib, a small molecule targeting KRAS, produced results described as practice-changing at ASCO 2026, offering a new approach to one of oncology's hardest tumours.
Early data from a Phase 1 study of VERVE-102, a base-editing therapy targeting PCSK9, show substantial LDL-cholesterol reductions at high doses, though the therapy remains at an early investigational stage.
Disabling the transcription factor NFIL3 in engineered CAR T cells prolonged their anti-tumour activity in mouse models, according to new research reported by ScienceDaily.
The bispecific antibody ivonescimab, developed in China, showed a survival benefit in squamous cell lung cancer, though researchers called for follow-up in more diverse patient populations.
A trial presented at ASCO 2026 found that substantially reduced doses of nivolumab retained efficacy in head and neck squamous cell carcinoma, a finding with potential relevance to treatment access in lower-income settings.
The Supreme Court ruled unanimously that Hikma Pharmaceuticals did not infringe patents held by Amarin, in a decision with broad implications for generic drug manufacturers and skinny-label litigation.
New NHS England data show that mobile scanning units deployed at supermarkets, sports stadiums and high streets have detected 10,678 lung cancers, more than three-quarters at stages one or two.
A new Cancer Research UK analysis argues that targeting the earliest detectable cancer-driving changes in high-risk individuals could prevent more cancers, but requires coordinated policy support to reach its potential.
A specialist First Opinion piece in STAT News draws three lessons from the world's first randomised trial of a multi-cancer early detection blood test, which did not meet its primary endpoint.
Following positive trial results reported at ASCO 2026, analysts and clinicians are examining how the KRAS(G12D) inhibitor daraxonrasib might be extended to other KRAS-driven tumour types.
A late-stage trial of Otsuka's Voyxact showed statistically measurable but smaller-than-anticipated slowing of kidney function decline in patients with IgA nephropathy, an autoimmune kidney disease with a genetic component.
Cancer Research UK analysis shows melanoma incidence has reached its highest recorded level in the UK, raising questions about prevention, surveillance, and the role of genetic risk factors.
A new computational system named PerturbFate tracks how diverse genetic mutations reshape cell fate over time, identifying convergent regulatory nodes that may represent targets shared across many cancer types.
A study integrating TCGA data with multiplex immunofluorescence identifies Z-DNA binding protein 1 as a hub gene correlating with cytotoxic T-cell infiltration in head and neck squamous cell carcinoma that resists PD-1 blockade.
Additional reporting and commentary from ASCO 2026 consolidates the picture around Revolution Medicines' daraxonrasib, with coverage noting that demand from patients is already outpacing access to the investigational drug.
A new systematic review published in 2026 concludes that prostate-specific antigen blood testing likely reduces the risk of death from prostate cancer, though over-diagnosis and over-treatment remain concerns.
A large-scale study genetically characterising feline tumours has identified conserved cancer-driving mutations across cats, dogs and humans, including genes associated with aggressive breast cancers.
A new study shows MYC protein recruits DNA-repair machinery at break sites, suggesting a mechanism by which tumours recover from chemotherapy and radiotherapy damage.
Cancer Research UK reports on a laboratory study suggesting cells retain an epigenetic record of past inflammatory episodes, potentially explaining the elevated cancer risk associated with inflammatory bowel conditions.
Case reports published in Communications Medicine describe clinical use of the MEK inhibitor trametinib in two patients with multiple non-ossifying fibromas attributed to somatic mosaic KRAS mutations.
A Cancer Research UK analysis explores the host genetic, microbial, and environmental factors that determine why gastric adenocarcinoma develops in roughly 1% of people infected with H. pylori.
About Genetic Current
Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.
Join the Evagene Alpha Waiting List